Biobank中文Project inquiry
ApplicationsNavigation menu
R&D ServicesModels & ProductsApplicationsTechnologyEvidence & ResourcesHow We WorkAbout TRiCBIONews & EventsBiobankProject inquiry中文

Application

Small-molecule & targeted therapy studies

Compare small-molecule dose responses and combinations in human organoids, with mechanistic assays to investigate differences across models.

Discuss a small-molecule studyExplore evidence and study options ↘

Study focus

Questions we can help answer

  1. 01What dose-response profile does the candidate show?
  2. 02What explains differences across models or samples?
  3. 03What does the combination add over either monotherapy?

Study workflow

From study goal to results

01

Candidate and study goal

Define the target and study goal: screen candidates, compare activity or investigate the mechanism of response.

02

Model and assay window

Select a biologically relevant model and confirm model performance, vehicle tolerance, positive-control response and assay window.

03

Dose, time and combinations

Use dose series, time points or combination matrices with consistent viability, morphology and mechanism-linked readouts.

04

Confirmation and ranking

Confirm initial hits and rank candidates using potency, maximum effect, selectivity and data quality.

Model options

Models for your study

Model & study services

Breast cancer PDO

Patient-derived breast tumor organoids for single-agent and combination studies, with PDO 2.0 / ALI considered when immune context is relevant.

↗Model & study services

Colorectal cancer PDO

Established from primary or metastatic colorectal tumors to compare drug response, tissue features and inter-sample differences.

↗Model & study services

HCC PDO / PDO 2.0

Use conventional PDOs for HCC efficacy studies. Immunotherapy or anti-angiogenic programs can add PDO 2.0, vascular-marker profiling or a purpose-built co-culture.

↗Model & study services

Renal cancer PDO

Compare targeted and immune-related treatment conditions in renal cancer PDOs using apoptosis and immune-cell readouts.

↗Model & study services

Pancreatic cancer PDO

Use conventional PDOs for pancreatic epithelial and drug-response studies, with ALI or custom co-culture added when stromal or immune context is important.

↗

Cases and evidence

Related studies and results

Study results

Glioma PDO 2.0: tumor features and treatment response

Tissue–PDO comparisons and lineage markers, plus CD31 and treatment readouts from a separate glioma study, show the model and functional data available for research.

↗Study results

Renal cancer PDO 2.0: apoptosis & immune response

Compare targeted, immune and combination treatments in renal cancer PDO 2.0 through histology, apoptosis and T-cell analysis.

↗Model & assay data

HCC PDO and PDO 2.0: culture format and tissue identity

Compare HCC PDO and PDO 2.0 culture morphology alongside source-tissue and marker images to examine model tissue features.

↗
Study design options

Plate format, throughput, dose range and hit criteria are adapted to the model and candidate; in vitro results support candidate comparison and the design of follow-on in vivo validation.

PROJECT DISCUSSION

Plan a small-molecule or targeted therapy study

The target, indication, candidate set and current dose, combination or mechanism question guide model selection, controls and study endpoints.

Discuss your study with our scientific teamSee how we work ↗